Standout Papers

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s dise... 2020 2026 2022 2024249
  1. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval (2020)
    Martin Tolar, Susan Abushakra et al. Alzheimer s Research & Therapy

Immediate Impact

4 by Nobel laureates 22 from Science/Nature 72 standout
Sub-graph 1 of 23

Citing Papers

A natural experiment on the effect of herpes zoster vaccination on dementia
2025 StandoutNature
Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
2024 Standout
2 intermediate papers

Works of Martin Tolar being referenced

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
2020 Standout
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”
2016

Author Peers

Author Last Decade Papers Cites
Martin Tolar 1110 372 482 437 33 1.7k
Paul Ardayfio 867 428 321 372 31 1.6k
Michael Egan 778 570 444 417 36 1.9k
Celedon Gonzales 894 345 695 367 31 1.6k
Amelia Marutle 903 230 421 794 33 1.7k
Susan Abushakra 982 432 446 294 42 1.5k
Chris Lane 836 225 321 636 12 2.0k
Gary Tong 845 346 317 787 34 2.1k
Michael Hüll 725 234 349 572 39 1.5k
L. Fernández‐Novoa 636 184 327 429 72 1.6k
Eleanor Drummond 1282 189 329 835 54 2.1k

All Works

Loading papers...

Rankless by CCL
2026